How publicly available hiring data revealed a story the stock price hasn’t priced in
Most investors read earnings reports. Some read SEC filings. Fewer read conference call transcripts. Almost nobody reads job postings.
That’s a mistake.
Job postings are one of the most honest forms of corporate communication that exist. Companies don’t post jobs for optics. They post jobs because they need people to do specific things, and those specific things tell you exactly where the business is going, what problems they’re solving, and sometimes, what they’re building toward.
⚠️ Reader notice: The author holds a position or has active interest in NSPR at the time of writing. Nothing in this article constitutes financial advice. All analysis is based on publicly available information. Do your own due diligence.
In the case of InspireMD (NSPR), three job postings and one executive departure tell a story that is, in my view, more revealing than anything in the most recent earnings release.
Let me walk you through what I found.
Job Posting #1: The One That Stopped Me Cold
- Title: Senior Process Engineer | Location: Charlotte, North Carolina
The job description opens with this line:
"InspireMD is establishing a second manufacturing line in the United States for the CGuard Prime product, which has recently launched in the United States. The person in this role will lead all manufacturing process improvement and capacity expansion initiatives at InspireMD's contract manufacturer in Charlotte, North Carolina."
Read that again slowly.
A second manufacturing line. In the United States. For a product that has been commercially available for less than nine months.
Why This Matters
InspireMD’s primary manufacturing operation is in Israel. That’s where CGuard has been produced since the company’s founding. The international business — Europe, Middle East, Asia-Pacific, Latin America — has been served from that facility for years.
When a company establishes a second manufacturing line in a new country, there are only a handful of reasons to do it:
- Reason 1: Demand is exceeding current capacity. The existing line can’t keep up with what’s coming. Given the 74% sequential growth in US revenue in Q4 2025, not an unreasonable interpretation.
- Reason 2: Supply chain risk management. Manufacturing in Israel carries geopolitical risk. Establishing US-based production reduces dependence on a single facility in a region that has experienced significant instability.
- Reason 3: Strategic asset preparation. A US-based manufacturing operation is a significantly cleaner asset for any potential strategic conversation than one dependent on overseas production. It simplifies supply chain due diligence, reduces integration complexity, and eliminates questions from any counterparty’s board about geopolitical exposure.
I want to be clear: I don’t know which of these reasons is primary. It may be all three simultaneously. But what I can say with confidence is this: companies don’t invest in second manufacturing lines speculatively. This decision was made based on specific visibility into future demand, strategic positioning, or both.
Charlotte Is Not An Accident
Charlotte, North Carolina is one of the largest medtech manufacturing hubs in the southeastern United States. The region has a deep ecosystem of contract manufacturers, biomedical engineers, and regulatory professionals with device manufacturing experience.
More importantly, InspireMD already has a contract manufacturer there. They’re not building from scratch. They’re expanding an existing relationship. That means this second line can be operational in months, not years.
The urgency embedded in that detail is worth sitting with.
Job Posting #2: The Revenue Signal
- Title: Field Clinical Specialist | Location: Morristown, New Jersey
In medical device sales, the Field Clinical Specialist is the person who stands in the procedure room with the physician during the case. They provide real-time technical support, answer questions, troubleshoot, and ensure the physician’s first experience with the device is a successful one.
You do not hire Field Clinical Specialists for procedures that don’t exist.
Morristown, New Jersey is home to Atlantic Health System, one of the largest integrated delivery networks in the northeastern United States, with multiple hospitals performing cardiovascular and vascular interventions. This isn’t a speculative hire for a market InspireMD hopes to enter. This is a support hire for a market they are actively penetrating.
Combined with the disclosure on the Q4 earnings call that 80+ centers have already performed cases and 200+ centers are in the VAC approval pipeline, this posting confirms that the commercial engine is running, and that the company is staffing to support procedures that are already scheduled or in the near-term pipeline.
Job Posting #3: The Infrastructure Signal
- Title: Clinical Affairs Manager | Location: United States (Remote)
Clinical Affairs sits at the intersection of commercial and regulatory. A Clinical Affairs Manager manages ongoing studies, interfaces with physician investigators, supports label expansion submissions, and builds the clinical evidence infrastructure that supports both regulatory approvals and commercial adoption.
Hiring for this role now, while a TCAR indication approval is pending at FDA and C-GUARDIANS II data is about to be presented publicly for the first time, signals that InspireMD is building for multiple regulatory submissions simultaneously.
This is not a company managing its current business. This is a company building for what comes next.
The Departure That Nobody Asked About
On February 27, 2026, InspireMD formally notified Andrea Tommasoli, its Chief Operating Officer, that he was being terminated. Under the terms of his French employment contract, he was relieved of operational duties effective April 1, 2026, with his formal employment ending September 1, 2026. His severance: approximately €61,000.
The market read this as a red flag. A COO departure during a critical commercial launch. Leadership instability. Execution risk.
I think the reality is more nuanced, and more interesting.
The Strategic Context First
Tommasoli joined InspireMD in November 2020 as SVP of Global Sales & Marketing. His background was specifically European, neurosurgery sales at Integra LifeSciences, neuromodulation at St. Jude Medical France. He was promoted to COO in March 2023.
That profile made complete sense for InspireMD between 2020 and 2024. The company’s revenue was almost entirely international. Europe was the primary commercial market. A COO with deep European medtech relationships, operating under French employment law, based in France, was a reasonable fit for that phase of the company.
But InspireMD in 2026 is a fundamentally different company.
The FDA approval happened. The US launch happened. The market that will define InspireMD’s next five years is not France or Germany, it’s New Jersey, Texas, and California. Managing a US commercial launch of this complexity — VAC processes, IDN contracts, Medicare reimbursement, clinical support infrastructure across dozens of states — from an office in France, with a career built in European markets, is a structural mismatch.
The simplest explanation for the departure may be the most accurate: the job changed, and the company needed a different profile for the next phase.
That reading is supported by what replaced him. Pete Ligotti was appointed Executive Vice President and General Manager of North America, with over 30 years of US medtech commercial leadership experience. Dr. Peter Soukas was appointed Chief Medical Officer in November 2025, a practicing interventional cardiologist with direct carotid stenting experience.
The company didn’t just remove a COO. It upgraded the executive function for the market that matters most, with profiles specifically suited to the challenges ahead.
What Makes The Departure Unusual
That said, the mechanism of the departure is worth examining separately from the rationale.
Most C-suite departures in public companies are communicated carefully. Press releases talk about ‘pursuing new opportunities’ and ‘next chapters.’ The departing executive thanks the team. The CEO expresses gratitude for years of service. The language is deliberately soft, regardless of the actual circumstances.
InspireMD’s 8-K used none of that language. It described a formal termination under French employment law, with a specific date on which Tommasoli would be relieved of operational duties and a separate date on which his employment would formally end. The severance was €61,000 — modest by any C-suite standard, and notably low given the protections typically afforded under French labor law.
There are several possible explanations for that language. It could reflect the specific technical requirements of French employment law, which mandates precision in termination documentation. It could reflect documented performance issues that required a formal process.
The most straightforward reading remains the most credible one: the role changed, the profile required changed, and the company acted accordingly.
I don’t know which explanation is correct.
What I do know is that none of the institutional analysts on the March 18th earnings call asked about it. Not one.
Three analysts from Piper Sandler, Lake Street Capital Markets, and Maxim Group participated in the Q&A. Each asked multiple detailed questions about commercial metrics, pipeline, technology, and competitive positioning. None asked about the COO departure that had been announced three weeks earlier.
Analysts with limited Q&A time tend to prioritize forward-looking commercial questions over resolved personnel matters. The absence of questions about the departure likely reflects that, not necessarily anything more than that.
Either way, the silence is its own kind of signal.
What The Postings Tell You: Taken Together
Individual data points can be coincidental. Patterns are harder to dismiss.
Second manufacturing line in Charlotte, NC → Demand visibility or strategic asset preparation
Field Clinical Specialist in Morristown, NJ → Active cases in one of the largest IDN markets in the US
Clinical Affairs Manager hired nationally → Building infrastructure for multiple regulatory submissions simultaneously
COO terminated under French law with formal language and modest severance → Structural mismatch with next phase — or something more specific
Pete Ligotti as GM North America — 30+ years US experience → Precisely the right profile for what comes next
CMO with direct carotid stenting clinical experience → Physician credibility for institutional adoption and strategic conversations
Each of these decisions was publicly available. Each of them was made within a six-month window. Taken together, they suggest a company that appears to be building, rapidly and deliberately, for something beyond its current commercial stage.
What that ‘something’ is remains an inference, not a fact, and that distinction matters.
My interpretation is that management is preparing for a bigger next phase than the current revenue base alone would suggest.
But there are other explanations too: supply-chain redundancy, post-launch caution, or ordinary infrastructure-building after FDA approval. Those possibilities should stay on the table.
The job postings do not answer the question directly.
What they do, in my view, is narrow the range of plausible explanations, and make the status quo look less random than it first appears.
Next in the series: ‘InspireMD (NSPR) Competition: Why The Problem Isn’t Fully Solved Yet’, What the other players in carotid stenting actually offer, and why that matters for InspireMD’s position.
🟢 Disclosure: The author holds a position or has active interest in this name.
⚠️ I produce these analyses for my own enjoyment and because I’m always looking for new opportunities. I am not a financial professional, and I don’t have access to professional-grade tools or proprietary data. Everything here is built from publicly available information and my own reasoning — which means I can be wrong. I may not always see the full picture, and my views will change as new information emerges or as I come to understand data points I initially overlooked or underweighted. I only operate with cash positions — no leverage, no margin, no shorting. I never bet against the market or individual companies. My analysis reflects the company’s fundamentals, not its price action. The company is not its price, and the price is not the company. I express my own opinions. I am not receiving compensation to share this. I have no business relationship with any company whose stock is mentioned in this article. Nothing here is financial advice. Do your own due diligence.